Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152824 | 0.89 | MPO (0.38) | HRH3FGFR1FGFR2FGFR3SRC | |
| SCHEMBL5149212 | 0.87 | SRC (0.40) | HRH3FGFR1FGFR2FGFR3SRC | |
| SCHEMBL5148946 | 0.87 | SMN1; SMN2 (0.37) | HRH3FGFR1FGFR2FGFR3ATR | |
| SCHEMBL5148967 | 0.87 | HRH3 (0.36) | HRH3FGFR1FGFR2FGFR3ADORA2A | |
| SCHEMBL5149085 | 0.86 | SRC (0.38) | HRH3FGFR1FGFR2FGFR3ATR | |
| SCHEMBL5152823 | 0.86 | ADORA2A (0.41) | HRH3FGFR1FGFR2FGFR3ATR | |
| SCHEMBL5149059 | 0.85 | FGFR2 (0.35) | HRH3FGFR1FGFR2FGFR3HSD11B1 | |
| SCHEMBL5149200 | 0.84 | SRC (0.43) | FGFR1FGFR2FGFR3ADORA2AADORA1 | |
| SCHEMBL5152714 | 0.83 | SRC (0.38) | HRH3FGFR1FGFR2FGFR3ADORA2A | |
| SCHEMBL5149189 | 0.83 | SYK (0.42) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | HRH3 43/4885FGFR1 2680/4885FGFR2 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.